Eliquis (BMS/Pfizer) success in VTE trial AMPLIFY

BMS and Pfizer Inc. announced the results of the six month Phase III AMPLIFY trial of 5,395 patients with acute venous thromboembolism (VTE), which includes symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE). In this trial, Eliquis (apixaban), as a single-agent achieved the primary efficacy endpoint of non-inferiority to current standard of care (initial parenteral enoxaparin treatment overlapped with warfarin therapy) in the reduction of the composite endpoint of recurrent symptomatic VTE or VTE-related death. Eliquis also met the primary safety endpoint of superiority for major bleeding, with a 69 percent relative risk reduction (RRR) compared to current standard of care. Importantly, AMPLIFY demonstrated comparable results for the primary efficacy and safety endpoints between patients entering the study with a DVT or a PE. The findings were published online in New England Journal of Medicine.